Skip to main content

Table 5 COOP scores.

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

  

Baseline

SAMe

Celecoxib

 

Variable

N+

Mean

(SD)

Mean

(SD)

Mean

(SD)

Stdif.

Total Score

46

48.7

(8.7)

39.9*

(9.3)

39.8*

(11.3)

-0.01

Physical Condition

46

56.2

(20.4)

51.7

(19.1)

51.3

(18.2)

-0.02

Emotional Condition

46

37.6

(16.1)

33.5

(17.9)

34.8

(17.6)

0.07

Daily Work

46

47.1

(17.0)

34.3*

(14.4)

33.9*

(15.7)

-0.03

Social Activities

46

31.4

(15.4)

29.1

(13.1)

29.6

(15.6)

0.02

Pain

46

70.5

(14.1)

53.0*

(15.9)

50.9*

(19.2)

-0.10

Change in Condition

46

65.2

(13.3)

49.1*

(16.7)

47.8*

(18.6)

-0.05

Overall Condition

46

50.0

(16.1)

44.3*

(16.3)

41.3*

(16.0)

-0.19

Social Support

46

39.0

(24.6)

29.6*

(18.3)

32.6

(18.1)

0.17

Quality of Life

46

41.0

(13.9)

34.3*

(16.1)

36.1

(13.1)

0.11

  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us